Key approval paves way for European expansion, tapping into a $4 billion vet services market

关键的批准为欧洲扩张铺平了道路，开拓了40亿美元的兽医服务市场

ANN ARBOR, MI / ACCESSWIRE / May 6, 2024 / Zomedica Corp. (NYSE American:ZOM) ('Zomedica' or the 'Company'), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced that it has received CE certification for its VetGuardian® remote contactless monitoring system.

密歇根州安阿伯/ACCESSWIRE/2024年5月6日/Zomedica Corp.（纽约证券交易所美国代码：ZOM）（“Zomedica”或“公司”）是一家为马和伴侣动物提供即时诊断和治疗产品的兽医保健公司，今天宣布其VetGuardian®远程非接触式监测系统已获得CE认证。

The CE marking confirms that the VetGuardian system meets all EU health, safety, and environmental protection standards. Importantly, this significant milestone expands the market size for VetGuardian and enhances access for internationally based veterinarians seeking advanced solutions for their patients..

CE标志确认VetGuardian系统符合所有欧盟健康、安全和环境保护标准。重要的是，这一重要里程碑扩大了VetGuardian的市场规模，并增强了国际兽医为患者寻求先进解决方案的机会。。

'Receiving CE certification is a testament to the safety and performance of our VetGuardian monitor, allowing us to bring this advanced technology to veterinary professionals across the European Union and beyond,' stated Tony Blair, Chief Operating Officer of Zomedica. 'This milestone not only expands our market potential but also provides veterinarians with a tool that enhances patient care and operational efficiency.'.

Zomedica首席运营官托尼·布莱尔（TonyBlair）表示：“获得CE认证证明了我们的VetGuardian监护仪的安全性和性能，使我们能够将这项先进技术带给欧盟及其他地区的兽医专业人员。”这一里程碑不仅扩大了我们的市场潜力，而且为兽医提供了一种提高患者护理和运营效率的工具。”。

The VetGuardian system utilizes state-of-the-art radar technology for contactless monitoring of vital signs in animals, promoting stress-free care and saving time during patient monitoring, enabling optimized workflow and improved outcomes.

VetGuardian系统利用最先进的雷达技术对动物的生命体征进行非接触式监测，促进无压力护理，节省患者监测时间，优化工作流程，改善结果。

'The CE mark is a green light for us to accelerate our global expansion with one of our fastest-growing products,' said Kevin Klass, SVP sales at Zomedica. 'We're already receiving inquiries from customers around the world, and we can now meet this growing demand head-on.'

Zomedica销售副总裁凯文·克拉斯（KevinKlass）说，CE标志为我们加速全球扩张开了绿灯，我们的产品是增长最快的产品之一我们已经收到来自世界各地客户的询问，现在我们可以迎面满足这一不断增长的需求。”

The European veterinary market was valued at $4.0 billion in 2022 and is projected to reach $5.4 billion by 2027, according to data from EuroDev.

根据EuroDev的数据，2022年欧洲兽医市场价值40亿美元，预计到2027年将达到54亿美元。

'The completion of CE certification for the VetGuardian monitor marks a significant milestone for Zomedica, opening new avenues of growth as we continue to drive innovation in the veterinary health sector,' stated Larry Heaton, CEO of Zomedica. 'With expanded market access and enhanced credibility, Zomedica remains at the forefront of delivering positive change in animal healthcare.'.

Zomedica首席执行官拉里·希顿（LarryHeaton）表示：“VetGuardian monitor CE认证的完成标志着Zomedica的一个重要里程碑，为我们继续推动兽医健康领域的创新开辟了新的增长途径。”随着市场准入的扩大和可信度的提高，Zomedica仍然处于动物保健领域积极变革的前沿。”。

Interested distributors and veterinarians are encouraged to reach out and inquire about partnership and sales opportunities at sales@zomedica.com. For more information about Zomedica and its innovative products, visit www.zomedica.com

鼓励感兴趣的经销商和兽医联系并询问合作伙伴关系和销售机会sales@zomedica.com.有关Zomedica及其创新产品的更多信息，请访问www.Zomedica.com

About Zomedica

关于Zomedica

Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio includes innovative diagnostics and medical devices that emphasize patient health and practice health.

Zomedica是一家兽医健康公司，总部位于密歇根州安阿伯，专注于临床兽医未满足的需求，为马、狗和猫创造产品。Zomedica的产品组合包括强调患者健康和实践健康的创新诊断和医疗设备。

Zomedica's mission is to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.zomedica.com..

Zomedica的使命是为兽医提供提高生产力和增加收入的机会，同时更好地为他们护理的动物服务。有关更多信息，请访问www.zomedica.com。。

Follow Zomedica

跟随Zomedica

Email Alerts: http://investors.zomedica.com

电子邮件警报：http://investors.zomedica.com

LinkedIn: https://www.linkedin.com/company/zomedica

LinkedIn: https://www.linkedin.com/company/zomedica

Facebook: https://m.facebook.com/zomedica

脸谱网：https://m.facebook.com/zomedica

X (formerly Twitter): https://twitter.com/zomedica

X（以前的Twitter）：https://twitter.com/zomedica

Instagram: https://www.instagram.com/zomedica_inc

Instagram: https://www.instagram.com/zomedica_inc

Cautionary Note Regarding Forward-Looking Statements

关于前瞻性声明的注意事项

Except for statements of historical fact, this news release contains certain 'forward-looking information' or 'forward-looking statements' (collectively, 'forward-looking information') within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as 'plan', 'expect', 'project', 'intend', 'believe', 'anticipate', 'estimate' and other similar words, or statements that certain events or conditions 'may' or 'will' occur and include statements relating to our expectations regarding future results.

除历史事实声明外，本新闻稿包含适用证券法含义内的某些“前瞻性信息”或“前瞻性声明”（统称“前瞻性信息”）。前瞻性信息通常以“计划”、“预期”、“项目”、“打算”、“相信”、“预期”、“估计”等类似词语为特征，或陈述某些事件或条件“可能”或“将”发生，并包括与我们对未来结果的预期有关的陈述。

Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information..

虽然我们认为前瞻性信息中反映的期望是合理的，但不能保证这些期望会被证明是正确的。我们不能保证未来的结果、表现或成就。因此，没有人表示所取得的实际结果将与前瞻性信息中所述的全部或部分相同。。

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition..

前瞻性信息基于报表编制之日管理层的意见和估计，包括有关经济增长、对公司产品的需求、公司生产和销售产品的能力、我们预算资本和运营支出的充足性、我们的战略合作伙伴对其在我们的商业协议下的义务的满意度、我们实现业务计划和成本控制工作的能力以及新型冠状病毒对我们的业务、业绩和财务状况的影响的假设。。

Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to our ability to supply products in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products, including acceptance in international markets; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including produ.

我们的前瞻性信息受到各种风险和不确定性以及其他因素的影响，这些因素可能导致实际事件或结果与前瞻性信息中预期的结果存在重大差异。可能导致结果与前瞻性信息中表达的结果存在重大差异的一些风险和其他因素包括但不限于：临床研究的结果，普遍接受的会计原则的应用，这些非常复杂，涉及许多主观假设，估计和判断，以及我们的战略和业务计划是否会产生预期收益的不确定性；开发工作以及验证和确认研究的时间和结果的不确定性；商业化努力的时间和结果以及商业化努力的成本不确定性，包括发展内部销售队伍和管理我们的增长的成本；我们成功整合收购的能力不确定；我们根据客户需求提供产品的能力存在不确定性；任何所需监管批准的可能性和时间以及资本的可用性和成本的不确定性；识别和开发新产品和技术并取得商业成功的能力；兽医对我们产品的认可，包括在国际市场上的认可；来自相关产品的竞争；维持和改进产品和服务质量所需的支出水平；技术变化和法律法规变化；我们确保和维持战略关系的能力；我们的战略合作伙伴履行其在我们的商业协议（包括produ）下的义务。

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation.

本警示声明明确限定了本新闻稿中包含的前瞻性信息。我们没有义务更新任何前瞻性信息，以使这些信息符合实际结果或我们预期的变化，除非适用的证券立法另有要求。

Readers are cautioned not to place undue reliance on forward-looking information..

提醒读者不要过度依赖前瞻性信息。。

Investor Relations Contact:

投资者关系联系人：

Zomedica Investor Relations

Zomedica投资者关系

investors@zomedica.com

investors@zomedica.com

1-734-369-2555

1-734-369-2555

SOURCE: Zomedica Corp.

资料来源：Zomedica Corp。

View the original press release on accesswire.com

在accesswire.com上查看原始新闻稿